Department of research of papillomavirus and other oncoviruses

Diagnosis and treatment of cervical cancer (CC) is an important problem of women's reproductive health. Every year, more than 500,000 new cases of the disease are diagnosed worldwide, of which over 50% are fatal. In 1996, the human papillomavirus (HPV) was officially recognized by WHO as an etiologic factor in the development of CC. Knowledge of the mechanisms of CC development, from the moment of HPV infection to the development of CC, an average of 5-10 years pass, which makes this oncological disease today the most "manageable" and preventable. The costs of organizing and conducting cervical cancer screening, treating precancerous conditions (cryotherapy, electrocoagulation or conization of the cervix) are many times lower than the costs of treating advanced forms of invasive cervical cancer (extensive surgeries, radiation and chemotherapy, long-term rehabilitation).

The success of cervical cancer screening depends on the following factors: the degree of study of the epidemiology of the disease; the availability of a unified comprehensive screening program approved by the Ministry of Health; the level of public awareness and staff skills in the technique of taking, fixing a smear and filling out an accompanying document; the use of a database for analysis and determining the direction of further work. Of all the above factors, the most fundamental at the moment are informing the population and training medical personnel in the technique of collecting material. The quality of the cytological smear determines its test characteristics.

In this regard, the Research Institute of Virology is studying the effectiveness of using primary methods of screening for cervical cancer at the population level - liquid cytology (Pap test) and HPV DNA testing, with subsequent genotyping of the Human Papilloma Virus (HPV). The research project in collaboration with KOFIH “Improving research and diagnostics of the human papilloma virus (HPV) in the Republic of Uzbekistan” will contribute to the development of scientifically based recommendations for the use of the above-mentioned primary screening methods to identify precancerous conditions and further strengthen the health of women in our Republic, and will also contribute to increasing the potential of medical institutions in Uzbekistan.

Lokteva Lyubov Mikhailovna

Since May 5, 2023:

Head of the Research Department "Papillomavirus and Oncovirus"

WORK ACTIVITY

2004-2011 - Student of the Tashkent Pediatric Medical Institute.

2011-2014 - Master of the Tashkent Pediatric Medical Institute

2013-2014 - Manager at the British Pharma company

2014-2016 - Infectious disease doctor at the Kungirot District Medical Association

2016-2021 - Virologist at the Reference Laboratory at the Research Institute of Virology

2021-2023 - Master's student at the University of Hiroshima, Japan.

2023 - current year - Head of the Papillomavirus and Oncovirus Research Department at the Research Institute of Virology of the Republican Specialized Medical Center for Epidemiology, Microbiology, Infectious and Parasitic Diseases